Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Open Badges Research article

Quantitative real-time RT-PCR validation of differential mRNA expression of SPARC, FADD, Fascin, COL7A1, CK4, TGM3, ECM1, PPL and EVPL in esophageal squamous cell carcinoma

Nan Hu1, Luxia Qian1, Ying Hu2, Jian-Zhong Shou3, Chaoyu Wang1, Carol Giffen4, Quan-Hong Wang5, Yuan Wang5, Alisa M Goldstein1, Michael Emmert-Buck2 and Philip R Taylor1*

Author Affiliations

1 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA

2 Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA

3 Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing 100021, PR China

4 Information Management Services, Inc, Silver Spring, MD 20904, USA

5 Shanxi Cancer Hospital, Taiyuan, Shanxi 030013, PR China

For all author emails, please log on.

BMC Cancer 2006, 6:33  doi:10.1186/1471-2407-6-33

Published: 2 February 2006



Esophageal squamous cell carcinoma (ESCC) is one of the most malignant tumors and typically presents at an advanced and rapidly fatal stage. To better understand the role of genetics in the etiology and prevention of ESCC and to identify potential susceptibility genes as well as early detection markers, we previously compared tumor and matched normal tissues from ESCC patients from a high-risk area of China using cDNA expression microarrays and identified 41 differentially-expressed genes (13 over-expressed and 28 under-expressed).


In the current study, we validated and quantitated differential mRNA expression in a sample of nine of these 41 genes, including four that were over-expressed (SPARC, FADD, Fascin, COL7A1), and five that were under-expressed (CK4, TGM3, ECM1, PPL, EVPL), in 75 new ESCC patients using quantitative Real-time RT-PCR and the 2-ΔΔCT method to examine both tumor and matched normal tissue. In addition, we examined expression patterns for these genes by selected demographic and clinical characteristics.


Four previously over-expressed (tumor ≥2-fold normal) genes were all increased in the majority of new ESCC patients: SPARC was increased in 71% of patients, Fascin in 70%, FADD in 63%, and COL7A1 in 57%. Five previously under-expressed (tumor ≤0.5-fold normal) genes similarly showed decreased mRNA expression in two-thirds or more of patients: CK4 was decreased in 83% of patients, TGM3 in 77%, ECM1 in 73%, and PPL and EVPL in 67% each. In subset analyses, associations with age (for COL7A1), family history (for PPL and ECM1), and alcohol use (for SPARC and Fascin) were also noted.


These data indicate that these nine genes have consistent differential mRNA expression, validating results of our previous cDNA array results, and affirming their potential role in the early detection of ESCC.